ALK-Abelló
140
DKK
-1.41 %
Less than 1K followers
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-1.41%
-9.91%
-12.01%
-10.88%
-20.41%
+9.55%
+0.79%
+113.9%
+305.8%
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Read moreMarket cap
31.2B DKK
Turnover
29.79M DKK
Revenue
5.54B
EBIT %
19.7 %
P/E
38.04
Dividend yield-%
-
Financial calendar
6.5
2025
Interim report Q1'25
21.8
2025
Interim report Q2'25
13.11
2025
Interim report Q3'25
All
Research
Webcasts
Press releases
ShowingAll content types
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
ACARIZAX® approved in Canada for treatment of young children
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Den amerikanske lægemiddelmyndighed (FDA) godkender ODACTRA® til behandling af husstøvmideallergi hos yngre børn
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
Dagens aktienyheder 25/02: Skako, Agillic og ALK
ALK: Wrap up fra interview med CFO Claus Steensen Sølje og Head of IR Per Plotnikof
